As DNA-PKcs-deficient glioma cells are addicted to FEN1 mediation to overcome DNA replication stress, FEN1 holds significant promise as a therapeutic agent for DNA-PKcs-deficient cancers. This evidence concerns the gene PRKDC and central nervous system cancer.